Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Unknown 3Recruiting 3Not yet recruiting 3Active not recruiting 3Terminated 2Completed 2Withdrawn 1Approved for marketing 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 16HER2-positive Breast Cancer 3Neoplasms 1Locally Advanced Breast Cancer 1HER2+ Early or Locally Advanced Breast Cancer 1HER2+ Breast Cancer 1Gastrointestinal Neoplasms 1Feasibility 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasm Female 1Brain Neoplasms 1

Interventions

Trastuzumab 7Docetaxel 5pertuzumab 3pyrotinib 2neratinib 1liposomal doxorubicin 1envafolimab 1Protons 1Paclitaxel 1Metformin 1Carboplatin 1Capecitabine 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × HER2-positive Breast Cancer × pertuzumab × Clear all
NCT05985187 2023-08-14

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
412 enrolled
Breast

HER2-positive Breast Cancer

NCT05720026 2023-02-09

Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Unknown
560 enrolled
Breast

HER2-positive Breast Cancer

NCT03238495 2021-12-07

HERMET

University of Kansas Medical Center

Phase 2 Unknown
100 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡